Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Altasciences Doubles Size of PA CDMO Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Altasciences Doubles Size of PA CDMO Facility

The additional 35,000-sq.-ft. building in Philadelphia will include warehouse and cGMP manufacturing suites.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Altasciences, a Quebec-based early phase CRO/CDMO, began the expansion of its CDMO facility in Philadelphia, PA. The additional 35,000-sq.-ft. building directly adjoins the current location, and will be fully renovated to meet growing business needs.
 
The first phase of construction, including warehouse and cGMP manufacturing suites, is expected to be completed by the end of 2021. The new space will be configured to include a ~8,750-sq.-ft. warehouse, a ~8,750-sq.-ft. Grade C/D manufacturing area, and a 17,500-sq.-ft.  client-dedicated cGMP manufacturing area.
 
“This expansion ensures that we are in an excellent position to continue to meet the needs of our clients and remain at the forefront of pharmaceutical manufacturing technology. We look forward to seeing this ambitious project come to completion in the coming months,” says Ben Reed, Vice President, Manufacturing at Altasciences.
 
Altasciences acquired the Philadelphia CDMO facility in February of 2020, and purchased the new building in December of 2020.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics